NCM Capital Management’s AbbVie ABBV Stock Holding History

NCM Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.64M	Hold	7,519	–	–	0.59%	41
2025 Q4	$1.72M	Buy	7,519 +1	+0%	+$228	0.64%	34
2025 Q3	$1.74M	Sell	7,518 -180	-2%	-$36.7K	0.68%	32
2025 Q2	$1.43M	Hold	7,698	–	–	0.59%	39
2025 Q1	$1.61M	Hold	7,698	–	–	0.73%	30
2024 Q4	$1.37M	Hold	7,698	–	–	0.62%	35
2024 Q3	$1.52M	Hold	7,698	–	–	0.73%	29
2024 Q2	$1.32M	Hold	7,698	–	–	0.69%	34
2024 Q1	$1.4M	Sell	7,698 -50	-0.6%	-$8.62K	0.79%	28
2023 Q4	$1.2M	Sell	7,748 -54	-0.7%	-$7.87K	0.73%	35
2023 Q3	$1.16M	Sell	7,802 -50	-0.6%	-$7.34K	0.83%	27
2023 Q2	$1.06M	Sell	7,852 -45	-0.6%	-$6.6K	0.74%	35
2023 Q1	$1.26M	Buy	7,897 +4	+0.1%	+$612	0.94%	26
2022 Q4	$1.28M	Buy	7,893 +4	+0.1%	+$613	0.84%	34
2022 Q3	$1.06M	Sell	7,889 -16	-0.2%	-$2.3K	0.8%	36
2022 Q2	$1.21M	Sell	7,905 -96	-1%	-$14.7K	0.85%	38
2022 Q1	$1.3M	Buy	8,001 +35	+0.4%	+$5.08K	0.82%	35
2021 Q4	$1.08M	Buy	+7,966	New	+$941K	0.96%	29

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM Capital Management's ABBV Position: Q1 2026 in Review

NCM Capital Management held its AbbVie (ABBV) position steady in Q1 2026 at 7,519 shares worth $1.64M. The position accounts for 0.59% of the portfolio, ranked #41.

NCM Capital Management first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.74M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

NCM Capital Management held 7,519 shares of AbbVie worth $1.64M as of Q1 2026.
NCM Capital Management left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.59% of NCM Capital Management's portfolio in Q1 2026, its #41 holding.
NCM Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
NCM Capital Management's AbbVie position peaked at $1.74M in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on NCM Capital Management's 13F filing for Q1 2026, filed 15 May 2026.